Rheumatol Ther. 2023 doi: 10.1007/s40744-023-00589-3. Epub ahead of print
In the UPJOINT open label study, the proportion of patients with PsA, and an inadequate response to csDMARDs or bDMARDs, who achieved minimal disease activity with upadacitinib was in line with the results of previous studies at 24 weeks. No new safety signals were identified.
While previous studies have demonstrated that upadacitinib is an effective treatment in patients with PsA and an inadequate response to csDMARDs and bDMARDs, data on the safety and efficacy of upadacitinib in a real-world environment are lacking. The UPJOINT study shows that the efficacy of upadacitinib is consistent with the results of previous studies and supports it’s established safety profile.